Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
$9.48
-0.9%
$8.51
$4.00
$14.44
$809.31M0.681.18 million shs2.82 million shs
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$6.47
-0.2%
$6.79
$6.08
$16.76
$655.80M-1.291.14 million shs4.32 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.69
-1.1%
$12.51
$5.22
$27.38
$159.77M0.43153,886 shs1.62 million shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$17.00
-5.0%
$16.79
$11.51
$25.50
$888.93M-2.8671,580 shs33,521 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
0.00%+4.29%+25.90%+10.49%+124.64%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
0.00%+2.37%+1.25%-18.41%-53.05%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+1.28%-1.48%-12.96%+97.66%
Pharvaris N.V. stock logo
PHVS
Pharvaris
0.00%-5.50%+2.84%+8.28%-9.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
3.8422 of 5 stars
3.70.00.04.72.90.80.6
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2.1162 of 5 stars
3.62.00.00.01.62.50.0
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.0217 of 5 stars
3.50.01.72.72.61.71.3
Pharvaris N.V. stock logo
PHVS
Pharvaris
1.5676 of 5 stars
3.51.00.00.01.90.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
3.33
Buy$44.00364.14% Upside
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3.13
Buy$30.57372.51% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50140.35% Upside
Pharvaris N.V. stock logo
PHVS
Pharvaris
3.00
Buy$36.20112.94% Upside

Current Analyst Ratings Breakdown

Latest LFVN, DAWN, AVXL, and PHVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$32.00
6/5/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$27.00
5/14/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.00
5/7/2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$25.00
5/7/2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $27.00
4/29/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$28.00
4/7/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
4/7/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
4/3/2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
3/31/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/A$1.42 per shareN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$131.16M5.00N/AN/A$4.99 per share1.30
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.80$0.88 per share14.39$2.05 per share6.19
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/A$5.54 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$43M-$0.55N/AN/AN/AN/A-40.93%-36.38%8/5/2025 (Estimated)
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$95.50M-$0.71N/AN/AN/A-42.66%-14.98%-13.04%7/8/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.39N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$145.24M-$3.01N/AN/AN/AN/A-54.02%-50.36%8/13/2025 (Estimated)

Latest LFVN, DAWN, AVXL, and PHVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q2 2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$0.16-$0.13+$0.03-$0.13N/AN/A
5/13/2025Q1 2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.80-$0.89-$0.09-$0.89N/AN/A
5/6/2025Q1 2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
4/7/2025Q4 2024
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.74-$0.68+$0.06-$0.68N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/AN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.42%N/A26.09%3 Years
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/AN/A

Latest LFVN, DAWN, AVXL, and PHVS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/A
6.74
6.74
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/A
10.62
10.55
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
11.10
11.10

Institutional Ownership

CompanyInstitutional Ownership
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
31.55%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
87.95%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A

Insider Ownership

CompanyInsider Ownership
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
11.00%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
6.20%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
4085.37 million75.98 millionOptionable
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
60101.36 million95.08 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Pharvaris N.V. stock logo
PHVS
Pharvaris
3052.29 millionN/ANot Optionable

Recent News About These Companies

Pharvaris (NASDAQ:PHVS) Trading Down 4.9% - What's Next?
Pharvaris Announces Annual Meeting of Shareholders

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anavex Life Sciences stock logo

Anavex Life Sciences NASDAQ:AVXL

$9.48 -0.09 (-0.94%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$9.45 -0.03 (-0.31%)
As of 06/27/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Day One Biopharmaceuticals stock logo

Day One Biopharmaceuticals NASDAQ:DAWN

$6.47 -0.01 (-0.15%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$6.46 0.00 (-0.08%)
As of 06/27/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.69 -0.14 (-1.09%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$12.66 -0.04 (-0.28%)
As of 06/27/2025 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Pharvaris stock logo

Pharvaris NASDAQ:PHVS

$17.00 -0.90 (-5.03%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$16.90 -0.10 (-0.59%)
As of 06/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.